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In this issue we are pleased to introduce a new series of manuscripts dedicated toCardiovascular Genomic Medicine. The sequencing of the human genome was a
seminal event which provided the opportunity to define disease in terms of its genetic
or genomic basis and, therefore, to design diagnostic and therapeutic technologies
directed toward the individual patient. Although in its infancy, genomics promises to
revolutionize the way we practice medicine. Therefore, we felt that it was important to
review the current status and future applications of medical genetics/genomics with an
emphasis on the clinical perspective. Dr. Geoffrey Ginsberg has organized a series of
manuscripts authored by leaders in the field which address genetic/genomic medicine
as it applies to cardiovascular disease. We have specifically sought to link genetic/
genomic advances to clinical disorders such as heart failure and arrhythmias. Individual
manuscripts will address topics such as deoxyribonucleic acid-based risk assessment,
cardiac arrhythmias, proteomics and novel biomarkers for acute coronary syndrome
and other syndromes, molecular imaging, congestive heart failure based on molecular
phenotyping, and pharmacogenomics. These manuscripts should arm cardiovascular
specialists with knowledge of the state-of-the-art, as well as prepare them for future
applications.
In the current issue Dr. Ginsberg and colleagues provide an overview of the
emerging field of cardiovascular genomic medicine. They point out that, as is so often
the case, newly developed technologies have enabled the acquisition of novel informa-
tion uponwhich to base our approach to cardiovascular diagnosis and treatment. They
review the evidence linking genomics and vascular disease, the importance of the
ribonucleic acid “expression pattern” in converting genotype to phenotype, and the
significance of proteins as biomarkers. The authors nicely delineate how genetic
variation can determine the response of an individual to a given pharmacologic agent,
and the potential of pharmacogenomics to guide our therapy in the future. We
anticipate that this series will not only be an excellent source of immediate knowledge,
but also serve as a reference as cardiovascular genomic medicine evolves in the years to
come. See page 1615.
—Anthony N. DeMaria, MD, MACC, Editor-in-Chief, Journal of the American
College of Cardiology.
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Focus Issue:
Cardiac Regeneration
Theability to achieve regeneration of heartmuscle is examined by six papers in thisfocus issue. Two clinical trials are reported in this issue using either granulocyte-
macrophage colony-stimulating factor (CSF) or granulocyte CSF. Both trials were
stopped early secondary to a1 in 10 chance of suffering amyocardial infarction with
these agents. An accompanying editorial suggests that high doses of these factors create
a pro-inflammatorymilieu that leads tomonocyte translocation andplaque rupture. In
a rat model of acute myocardial infarction, granulocyte CSF and stem cell factor did
improve left ventricular function during dobutamine infusion. However, there was no
evidence for the recruitment or regeneration ofmyocytes. In a positive study, the IACT
study used autologous bone marrow transplantation to stimulate myocyte growth in
patients with chronic ischemic heart disease. Follow-up single-photon emission com-
puted tomography, positron emission tomography, and ventriculography showed
improved left ventricular function with the development of viable tissue, suggesting
that new myocytes and the necessary blood flow had developed. The final paper
describes the fairly recent and controversial transition from the belief that the number
of myocytes is fixed at birth to the understanding that the heart is capable of regener-
ation; the focus currently is on finding the optimalmethod for recruiting stem cells and
stimulating them to develop into functional myocytes. One method for stimulating
cardiac regeneration is to use cytokines that release stem cells from the bone marrow.
This focus issue demonstrates the great potential of cardiac regeneration, but also
highlights the many areas of uncertainty and risk in developing these methods. See
pages 1636, 1643, 1649, 1651, 1659, and 1662. See figure.
Page 1672
Interventional Cardiology
No Evidence of Late Reactions to Sirolimus Stents
A non-biodegradable polymer is used to attach sirolimus to the struts of sirolimus-eluting stents (SES). Eighty percent of the drug is eluted in the first 30 days, but
the polymer remains, raising concern that this may provoke a chronic inflammatory
response. Aoki and colleagues report the four-year results of serial intravascular ultra-
sound studies done on a cohort of patients with SES. Comparing themeasurements at
two and four years, they report that there is no significant change in neointimal volume
over this period and there is a slight decrease in the volume of plaque behind the struts.
This area behind the struts became more echogenic over time, suggesting that the soft
lipid material is being slowly replaced with more stable fibrous tissue. This study
suggests that there is no significant chronic inflammatory response that would decrease
the effectiveness of SES over long time periods. See page 1670. See figure.
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Chronic Coronary
Artery Disease
High ADMA Levels Inhibit Endothelial Progenitor Cells
Asymmetric dimethylarginine (ADMA) is created when arginine residues in pro-teins are methylated; the reasons for this methylation are poorly understood.
Previous research has shown that ADMA inhibits nitric oxide synthases and is elevated
in numerous conditions, including diabetes, hyperlipidemia, and hyperhomocysteine-
mia.Thumand colleagues examined the levels ofADMA inpatientswith stable angina
and found higher levels in those with angiographically proven atherosclerosis. The
more circulating ADMA there was, the fewer circulating endothelial progenitor cells
(EPCs). In vitro, ADMA inhibited endothelial maturation from EPCs; interestingly,
this inhibition could be reversed by rosuvastatin. Thus, ADMA appears to be an
emerging cardiac risk factor that has several detrimental effects on endothelial health
and function. See page 1693. See figure.
Page 1724
Cardiac Rhythm Disorders
Predicting Who Will Benefit From an ICD
In this issue, two articles and an editorial address the question: Which patientsbenefit from implantable cardioverter-defibrillators (ICDs)? Singh, writing on
behalf of the MADIT-II Investigators, found that both baseline characteristics and
clinical events during follow-up could predict subsequent appropriate ICD therapy.
Significant risk factors included not using beta-blockers, using digoxin, and being
subsequently hospitalized for a cardiac etiology. Elhendy and colleagues followed 90
patients who had an ICD and who subsequently were referred for stress echocardiog-
raphy.Therewas a strong correlation between inducible ischemia and subsequent need
for ICD therapy. In an editorial, Fisher summarizes the importance of these and other
studies: patients have disease that progresses at an unpredictable rate, some patients
have warning signs before a cataclysmic event. The challenge for the physician is to
recognize these warning signs in time. See pages 1712, 1721, and 1727. See
figure.
Hypertrophic Cardiomyopathy
Mutation in MyBPC Leads to Slowly Progressive HCM
Multiple mutations in several different sarcomeric proteins can result in thephenotype of hypertrophic cardiomyopathy (HCM), yet little is known about
the rate of disease progression among the different mutations. Kubo and colleagues
describe a cohort of 39 individuals found to have the V592fs/8 mutation in the
myosin-binding protein C (MyBPC) gene; this mutation results in a prematurely
truncated protein that does not have the usualmyosin and titin binding sites. Thirty of
these 39 individuals had evidence ofHCM, including all of the subjects over the age of
65 years. Clinical follow-up over nearly 10 years suggests that the mutation leads to a
slowly progressive cardiomyopathy with frequent clinical events. An accompanying
editorial by Ackerman and colleagues places this study in context and points to future
avenues of study that need to be pursued. See pages 1737 and 1744.
